linjc16/ctgov huggingface dataset:
The Use of Capsaicin Challenge for Diagnosis, Monitoring and Follow-up of Chronic Cough.

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether the capsaicin challenge can improve the diagnosis, treatment, monitoring and follow-up in patients with chronic cough.

Detailed Description
-----------------
Capsaicin is administrated in incremental concentrations with two inhalations of normal saline solution. Patients are instructed to exhale to functional residual capacity and than to inhale through the mouthpiece for 1 second (single breath inhalation). The number of coughs in the first 10 seconds after each inhalation is counted. C2; the concentration of which the patient responded by 2 coughs, C5;the concentration of which the patient responded by 5 coughs. The challenge ends at C5.

Official Title
-----------------
The Use of Capsaicin Challenge for Diagnosis, Monitoring and Follow-up of Chronic Cough.

Conditions
-----------------
Chronic Cough

Intervention / Treatment
-----------------
* Other: capsaicin challenge


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with persisting cough for more than 3 months, without known respiratory or lung diseases Exclusion Criteria: Diagnosis of respiratory or lung diseases of any kind
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: chronic cough<br>Capsaicine challenge in chronic cough patients | Other: capsaicin challenge<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| cough reflex hypersensitivity |  | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
chronic cough, cough reflex hypersensitivity, capsaicin
Dosing Study of Remifentanil for Smooth Removal of the Laryngeal Mask Airway (LMA)

Study Overview
=================
Brief Summary
-----------------
The investigators attempted to determine the optimal effect-site concentration of remifentanil for smooth removal of the LMA from propofol anesthesia.

Detailed Description
-----------------
At the end of the surgery, propofol infusion was stopped and remifentanil was titrated to predetermined (initial concentration 1.0 ng/ml for the first patient). LMA removal was performed when the patients opened their eyes and spontaneous respiration and adequate tidal volume and ventilatory frequency were confirmed.

Official Title
-----------------
Effect-site Concentration of Remifentanil for Smooth Removal of the LMA From Propofol Anesthesia

Conditions
-----------------
Drug Usage

Intervention / Treatment
-----------------
* Drug: remifentanil
* Device: laryngeal mask airway (LMA)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ASA I-II patients undergoing general anesthesia for short elective surgery (<1 hr) Exclusion Criteria: G-E reflux obesity (BMI>30) anticipated difficult airway

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: remifentanil<br>LMA removal was accomplished when remifentanil was maintained a predetermined concentration throughout the emergence periods. | Drug: remifentanil<br>* The concentration of remifentanil was determined by modified Dixon's up-and-down method, starting from 1.0 ng/ml (0.2 ng/ml as a step size)<br>* Other names: Ultiva;Device: laryngeal mask airway (LMA)<br>* LMA was removed when the patients opened their eyes, and spontaneous respiration and adequate tidal volume and ventilatory frequency were confirmed<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| smooth removal of LMA | the response of patients to the removal of LMA (classified as either 'success [smooth emergence]' or 'failure') during infusion of remifentanil. | from end of surgery to removal of LMA (participants will be followed for the emergence periods, an expected average of 15 min). | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
LMA removal, remifentanil, propofol
Rectrospect - a Retrospective Study of Treatment Response

Study Overview
=================
Brief Summary
-----------------
Biopisies from patients diagnosed with rectal cancer between 2007-2019 will be cut into 4-6 micrometer thin sections for morphology and immunostaining. Every section will be numbered with a code that is connected to the patients personal identification number and the code list will be kept separately from the biopsies in a password protected file on the Sahlgrenska University Hospital server. Patient data and outcome regarding response to treatment will be collected from patient charts and the Swedish ColoRectal Cancer Registry, but all data will be numbered with the same code number and all results will be kept away from the code list. In order to achieve the stated aims, that is, to study how the molecular and cellular characteristics of the tumour and its surrounding microenvironment as well as the interaction of tumour cells and immune cells affect treatment response, several molecular and cellular techniques and assays may be applied.

Official Title
-----------------
Rectrospect - a Study on the Immun Cell Infiltrate in a Retrospective Rectal Cancer Cohort.

Conditions
-----------------
Rectal Neoplasms

Intervention / Treatment
-----------------
* Radiation: Radiotherapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Rectal cancer and treatment between 2007 and 2019 Exclusion Criteria: No rectal cancer or no neoadjuvant treatment
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with pathological response to treatment<br>Response evaluated using the pathology report | Radiation: Radiotherapy<br>* Patients have received neoadjuvant radiotherapy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Immun cell infiltrate in pathology sections from the tumour | Number of of CD3+ and CD8+ cells in the tumour in relation to response to treatment | Biopsies taken preoperatively |
Radlink GPS Provide a Valid Intra-operative Assessment of Acetabular Inclination and Anteversion

Study Overview
=================
Brief Summary
-----------------
Evaluate the accuracy of Radlink System in determining acetabular cup placement and limb length evaluation during Anterior hip replacement as measured intraoperative with C-Arm visualization and confirmed with digital x-ray at 4-6 weeks postoperatively.

Detailed Description
-----------------
Evaluate the accuracy of Radlink System in determining acetabular cup placement and limb length evaluation during Anterior hip replacement as measured intraoperative with C-Arm visualization and confirmed with digital x-ray at 4-6 weeks postoperatively. GPS may improve total hip replacement by allowing surgeons to measure the exact position of components placed during surgery and there is a question whether RADLINK helps surgeons place the acetabular cup (the part that goes into the hip bone) component in a precise position. The objective of the study is to determine whether GPS gives surgeons reliable, valid information about the orientation of the cup component. The surgeons need to collect data to help clarify this issue.

Official Title
-----------------
Radlinik GPS Provide a Valid Intra-operative Assessment of Acetabular Inclination and Anteversion

Conditions
-----------------
Implant Position in Total Hip Replacement

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Both: both female and male participants are being studied. Minimum Age: Age of participants is between 20 years - 75 years. Accepts: Persons who are in need of a total hip replacement Exclusion Critieria: Has an existing condition that would compromise participation Had previous surgery on affected hip

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison of intra-op values for acetabular inclination and ante version, limb length using Radlink with those obtained and 4-8 weeks postop digital films. |  | 4-8 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Accuracy of cup placement/limb length with Radlink to a predetermined value and what surgeon obtains with Radlink guidance. |  | 4-8 weeks |
Detection of Chlamydia (CT) and Gonorrhea (NG)

Study Overview
=================
Brief Summary
-----------------
To evaluate the illumigene Chlamydia and illumigene Gonorrhea assays, using the illumipro-10, with male urine, female urine, physician-collected (medical professional) endocervical swabs and self-collected vaginal swabs taken from symptomatic and asymptomatic patient populations.

Official Title
-----------------
Clinical Study Protocol for the Illumigene® Chlamydia and Illumigene® Gonorrhea DNA Amplification Assays

Conditions
-----------------
Chlamydia, Gonorrhea

Intervention / Treatment
-----------------
* Device: illumigene CT and NG assays, illumipro-10


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female Any ethnicity or race Subject >14 and <89 years of age Subject who voluntarily gives written informed consent; not applicable for leftover specimens Symptomatic or asymptomatic subject who is able and willing to provide the required urine and swab samples for testing for CT and NG Leftover urine specimens Exclusion Criteria: Subjects < 14 or >90 years of age Subjects who are unwilling to sign the written informed consent; not applicable for leftover specimens Subject who is unwilling or unable to provide the required urine and swab samples for testing; not applicable for leftover specimens Individuals who have been on antibiotic medications within 10 days. Multiple sets of specimens from the same subject at different office visits Samples collected or processed in manner other than specified in the study protocol and Investigational Use Only package insert. Frozen archived specimens

Ages Eligible for Study
-----------------
Minimum Age: 14 Years
Maximum Age: 89 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Specimen Collection<br> | Device: illumigene CT and NG assays, illumipro-10<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Qualitative detection of Chlamydia trachomatis and/or Neisseria gonorrhoeae (GC) to aid in the diagnosis of chlamydial and/or gonococcal urogenital disease | Testing of each set of subject samples is completed within 60 days of sample collection | Up to 60 days |
Long-term Outcomes of Colonic Stent as a Bridge to Surgery for Malignant Large-bowel Obstruction

Study Overview
=================
Brief Summary
-----------------
Study of long-term outcomes of colonic stent as a bridge to surgery for malignant large-bowel obstruction.

Detailed Description
-----------------
Prospective observational with retrospective analisis study of patients with left-sided malignant colonic obstruction undergoing stenting between April 2006 and April 2018 in Parc Tauli University Hospital. We assessed all patients with intent-to-treat and per protocol analyses in postoperative and long-term follow-up variables.

Official Title
-----------------
Long-term Outcomes of Colonic Stent as a Bridge to Surgery for Malignant Large-bowel Obstruction

Conditions
-----------------
Stent Occlusion, Long-term Oncologic Results

Intervention / Treatment
-----------------
* Device: stenting


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients aged over 18 years diagnosed with complete malignant colonic obstruction confirmed by CT. Elective surgery. Location in transverse, left or sigmoid colon. Patients who signed the informed consent documentation and agreed to undergo the procedure. Exclusion Criteria: Benign pathology and palliative treatment. Unresectable lesion (intraoperative), severe ischemia or cecal perforation, fecal or advanced purulent peritonitis, emergency surgery. Previous chemotherapy.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: stenting|stenting procedure in patients diagnosed malignant large bowel occlusion|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| long-term outcomes | survival rates | 2 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| anastomotic leak | surgery | 30 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Malignant colonic obstruction, self-expandable metallic stent
Phase 2 Hypofractionation Study Using Proton Beam Therapy for Prostate Adenocarcinoma

Study Overview
=================
Brief Summary
-----------------
Phase 2 hypofractionation study usion proton beam therapy for prostate adenocarcinoma

Official Title
-----------------
Phase 2 Hypofractionation Study Using Proton Beam Therapy for Prostate Adenocarcinoma

Conditions
-----------------
Prostate Adenocarcinoma

Intervention / Treatment
-----------------
* Radiation: proton beam therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Biopsy proven prostate adenocarcinoma Stage: T1-T2cN0M0 ECOG performance status: 0-2 Signed study specific informed consent prior to study entry Exclusion Criteria: Postoperative residual or recurrent tumor Evidence of distant metastases Previous irradiation for the tumor in the same location Adjuvant anti-androgenic hormonal therapy High risk group (NCCN guide line)
Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Arm 1<br>27pt/60CGE/20fx/5wks to PGTV(mon, tue, thu, fri; 4/wk) | Radiation: proton beam therapy<br>* hypofractionation study using proton beam therapy for prostate adenocarcinoma<br>|
| Experimental: Arm 2<br>27pt/54CGE/15fx/5wks to PGTV (mon, wed, fri; 3/wk) | Radiation: proton beam therapy<br>* hypofractionation study using proton beam therapy for prostate adenocarcinoma<br>|
| Experimental: Arm 3<br>27pt / 47CGE/10fx/5wk to PGTV(tue, thu;2/wk) | Radiation: proton beam therapy<br>* hypofractionation study using proton beam therapy for prostate adenocarcinoma<br>|
| Experimental: Arm 4<br>27pt/ 35CGE/ 5fx/2.5wk to PGTV(the, thu; 2/wk) | Radiation: proton beam therapy<br>* hypofractionation study using proton beam therapy for prostate adenocarcinoma<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| clinical outcomes | To evaluate biochemical failure-free survival (BCFFS) | up to 5years from a initial follow-up | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| acute toxicity | to evaluate acute toxicities by CTCAE version 3.0 | up to 5years from a initial follow-up | 
| late toxicity | to evaluated late toxicities by CTCAE version 3.0 | up to 5years from a initial follow-up | 
| overall survival | to evaluated overall survival | up to 5years from a initial follow-up | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
hpofractionation study using proton beam therapy
Evaluation of Rebound Effect After Withdrawal of Proton Pump Inhibitor in Geriatric Population

Study Overview
=================
Brief Summary
-----------------
Proton pump inhibitor are frequently used and are short term well tolerated ; but few studies show there are adverse event in long term prescription like fracture or pulmonary infection to Clostridum difficile. The fact is that multi medication in old patient increase the iatrogenic risk and decrease the medication compliance. The Proton pump inhibitor (PPI)are overused in this patient category.Several studies suggest the existence of a rebound effect when people were treated more than 8 weeks ; this effect seems to appear around 14 days after with hyperacidity symptoms. But there are no studies about old patient. So in this context the aim of the study is to evaluate the prevalence of rebound effect occurence after the end of PPI 8 weeks treatment.

Official Title
-----------------
Evaluation of Rebound Effect After Withdrawal of Proton Pump Inhibitor After 8 Weeks of Treatment in Geriatric Population

Conditions
-----------------
Proton Pump Inhibitor

Intervention / Treatment
-----------------
* Drug: Antacids


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients hospitalized in post acute and rehabilitation service more than 65 years old PPI prescription more than 8 weeks Exclusion Criteria: PPI prescription under 8 weeks PPI prescription for digestive haemorragy

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Antacids|number aof antacids treatment after PPI stop|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of antacids used |  | Day 14 after end of treatment |
Study to Evaluate the Digestive Tolerability of ART44 Versus ART®50 in Patients With Osteoarthritis of the Knee

Study Overview
=================
Brief Summary
-----------------
The primary objective of this study, comparing ART 44 to ART 50, will be the evaluation of digestive tolerability (and in particular of diarrhoea).

Official Title
-----------------
Randomised, Comparative, Double-blind, Parallel-group Study to Evaluate the Digestive Tolerability of ART44 Versus ART®50 in Patients With Osteoarthritis of the Knee

Conditions
-----------------
Knee Osteoarthritis

Intervention / Treatment
-----------------
* Drug: ART 44
* Drug: ART 50


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Female or Male, aged 40 to 80 years, outpatient; Presenting with internal femorotibial osteoarthritis: Symptomatic for more than 6 months; Meeting ACR clinical and radiological criteria; Overall mean VAS score of knee pain in last 24 hours > 40 mm (with no NSAIDs for over 72 hours and no analgesics for over 24 hours); Pain present for at least one day out of 2 in the month preceding enrolment; Radiological stage II to III (Kellgren and Lawrence) (image less than 12 months old). Exclusion Criteria: Associated predominant symptomatic femoropatellar osteoarthritis; Chondromatosis or villonodular synovitis of the knee; Paget's Disease.

Ages Eligible for Study
-----------------
Minimum Age: 40 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: ART 44<br>Evaluation of safety and efficacy at D-8, D0, W2, W4 and W12 | Drug: ART 44<br> <br> |
| Active Comparator: ART 50<br>Evaluation of safety and efficacy at D-8, D0, W2, W4 and W12 | Drug: ART 50<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To demonstrate the better digestive tolerability of ART44 versus ART 50 over a 1-month period, based on a clinically predetermined difference |  | Day 8, Day 0, Week 2, Week 4 and Week 12 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To compare the overall safety and efficacy of the two products |  | Day 8, Day 0, Week 2, Week 4 and Week 12 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
knee osteoarthritis